ArticleOncoTargets and therapy2019
Multiple myeloma with dural mater involvement.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Intracranial multiple myeloma masquerading as subdural hematoma: illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
- Article
- Clinical Proteomics of Biofluids in Haematological Malignancies.International journal of molecular sciences · 2021Review
- Intracranial plasmacytoma arising from dura mater secondary to multiple myeloma and presenting with sudden lethal intracerebral hemorrhage: A case report and literature review.Surgical neurology international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma is an incurable clonal B-cell malignancy which may present with neoplastic monoclonal plasma cells in either bone or soft tissues. Central nervous system (CNS) involvement such as dural myeloma or intraparenchymal infiltration, or with diffuse leptomeningeal involvement, is uncommon. Dural involvement of myeloma without parenchymal or leptomeningeal disease is an even rarer occurrence; therefore there are no established treatment guidelines for CNS myelomatosis. Here we reported a refractory MM patient progressed to dura mater involvement after the induction therapy but showed good response to lenalidomide treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.